• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    ALX Oncology Holdings Inc. - Common Stock (NQ: ALXO )

    1.620 +0.140 (+9.46%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about ALX Oncology Holdings Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
    Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development 
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces November Investor Conference Participation
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
    Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual... 
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
    Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma 
    From ALX Oncology
    Via GlobeNewswire
    Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
    Via Benzinga
    ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q2 2024
    ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
    From ALX Oncology
    Via GlobeNewswire
    Crude Oil Moves Lower; Moderna Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Nasdaq Surges 1%; Meta Posts Upbeat Earnings
    Via Benzinga
    Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
    ALX Oncology announces Phase 2 ASPEN-06 trial results for evorpacept in combination with trastuzumab, Cyramza, and paclitaxel for HER2-positive gastric/GEJ cancer. The trial shows significant... 
    Via Benzinga
    Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
    From ALX Oncology
    Via GlobeNewswire
    ALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024
    ALXO stock results show that ALX Oncology Holdings beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Appoints Allison Dillon as Chief Business Officer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
    From ALX Oncology
    Via GlobeNewswire
    ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
    From ALX Oncology
    Via GlobeNewswire
    Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. 
    Via Benzinga
    United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.